Product Description
Ticagrelor (Brilique™, Brilinta®), a cyclopentyl-triazolopyrimidine, is an orally active, reversible, and selective adenosine diphosphate (ADP) receptor antagonist indicated for use in patients with acute coronary syndromes (ACS). Ticagrelor has a faster onset of action and provides greater inhibition of platelet aggregation than clopidogrel. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25672642/)
Mechanisms of Action: P2Y12 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, China, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Serbia, Slovenia, Spain, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 14
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: COVID-19|Coronary Artery Disease|Influenza, Human|Ischemic Stroke|Myocardial Infarction|Pneumonia|Thrombosis
Phase 1: Acute Coronary Syndrome|Healthy Volunteers|Insomnia|Oncology Solid Tumor Unspecified|Stroke
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2021-003906-34 |
ANGIODAPT | P3 |
Active, not recruiting |
Coronary Artery Disease |
2029-07-21 |
2025-06-17 |
Treatments |
|
NCT06853535 |
PATH STROKE C | P3 |
Not yet recruiting |
Ischemic Stroke |
2027-06-30 |
2025-03-04 |
Primary Endpoints|Treatments |
|
NCT02735707 |
REMAP-CAP | P3 |
Recruiting |
Influenza, Human|Pneumonia|COVID-19 |
2026-02-01 |
2024-11-27 |
||
NCT06318481 |
TADCLOT | P3 |
Completed |
Myocardial Infarction|Thrombosis |
2025-02-20 |
8% |
2025-07-11 |
Primary Endpoints |
ACTRN12619001529134p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified|Healthy Volunteers |
2020-03-28 |
|||
CTR20243295 |
CTR20243295 | P1 |
Completed |
Acute Coronary Syndrome |
2024-12-17 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20233969 |
CTR20233969 | P1 |
Completed |
Acute Coronary Syndrome|Stroke|Myocardial Infarction |
2024-01-12 |
2025-04-29 |
Primary Completion Date |
|
NCT06671470 |
YZJ-1139-1-13 | P1 |
Active, not recruiting |
Insomnia |
2024-09-13 |
37% |
2024-11-05 |
Primary Endpoints |
CTR20132250 |
CTR20132250 | P3 |
Active, not recruiting |
Myocardial Infarction |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT06554821 |
D3560C00817 | P1 |
Completed |
Healthy Volunteers |
2024-10-08 |
12% |
2025-04-19 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06233266 |
TIC-025-23 | P1 |
Not yet recruiting |
Healthy Volunteers |
2024-07-19 |
50% |
2024-02-01 |
Primary Endpoints|Treatments |
CTR20242889 |
CTR20242889 | P1 |
Active, not recruiting |
Insomnia |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20250664 |
CTR20250664 | P1 |
Recruiting |
Acute Coronary Syndrome |
None |
2025-07-15 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
2023-507015-35-00 |
2023-507015-35-00 | P3 |
Recruiting |
Coronary Artery Disease |
2031-02-28 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/10/2025 |
News Article |
CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025 |
|
11/11/2025 |
News Article |
CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London |
|
11/07/2025 |
News Article |
NYU Langone Cardiologists Share Leading Research at AHA Scientific Sessions 2025 & Dr. Judith S. Hochman Honored with Research Achievement Award |
|
10/30/2025 |
News Article |
CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights |